Myriad Genetics | MYGN - Gross Profit On Sales


Myriad Genetics reported $146.8M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Agilent USD 990M 44M Mar/2026
Becton, Dickinson and Co. USD 2.32B 161M Jun/2026
Bio-Rad Laboratories USD 309.4M 35.8M Mar/2026
Bruker USD 416M 36.2M Jun/2026
Danaher USD 3.61B 20M Jun/2026
Illumina USD 770M 49M Jun/2026
J&J USD 18.55B 1.31B Jun/2026
Mettler Toledo International USD 555.82M 119.62M Mar/2026
Myriad Genetics USD 146.8M 3M Dec/2025
OraSure Technologies USD 11.34M 435K Dec/2025
Pacific Biosciences Of California USD 15.74M 601K Dec/2025
Quest Diagnostics USD 906M 33M Mar/2026
Quidel USD 223.9M 315.7M Jun/2026
Repligen USD 110.04M 1.75M Jun/2026
Revvity USD 416.87M 29.21M Jun/2026
Standard Biotools USD 11.31M 74K Mar/2026
Thermo Fisher Scientific USD 4.49B 146M Mar/2026
Veracyte USD 108.55M 7.39M Jun/2026
Waters USD 490M 52M Jun/2026